Cahide ERZURUM, Aysen HALAÇOĞLU, Tevfik Tanju YILMAZER, Murat SUHER

Metabolik sendromu olan ve olmayan obez hastaların antropometrik ölçümleri, yüksek sensitif CRP ve ürik asit düzeyleri açısından karşılaştırılması

Obezitenin morbidite ve mortaliteyi artırıcı etkisi bilinmektedir. Epidemiyolojik araştırmalarda metabolik sendromlu (MS) olgulardaki artış ile obezite epidemisi arasında yakın ilişki saptanmıştır. Bu çalışmanın amacı MS olan ve olmayan obez hastaların antropometrik ölçümleri, kardiyovasküler hastalık riskinde önemli olan yüksek sensitif CRP (hsCRP) ve ürik asit düzeyleri arasındaki ilişkinin değerlendirilmesidir. Materyal ve Metot: Polikliniğe başvuran 96 obez hasta kesitsel olarak değerlendirildi. Hastaların fizik muayene, antropometrik ölçümleri, karaciğer ve böbrek fonksiyon testleri, lipit parametreleri, ürik asit ve hsCRP düzeyleri değerlendirildi. Doksan-altı obez hastanın 58'i MS kriterlerini karşılarken, 38'i karşılamıyordu. Bulgular: Doksan-altı hastanın 77'si (%80) obez [Beden kitle indeksi (BKİ)≥30 kg/m²], 19'u (%20) ise morbid obezdi (BKİ≥40 kg/m²). Ürik asit düzeyi erkeklerde (p=0,00), hsCRP düzeyi ise kadınlarda daha yüksek bulundu (p=0,008). Metabolik sendromu olan obez ve morbid obez gruplar karşılaştırıldığında morbid obez grupta hsCRP düzeyleri istatistiksel olarak yüksek saptandı (p=0,036). Metabolik sendromu olmayan obez ve morbid obez gruplar karşılaştırıldığında morbid obez grupta yine hsCRP düzeylerinin daha yüksek olduğu görüldü (p=0,03). Sonuç: Bu çalışmada morbid obezlerde MS varlığından bağımsız hsCRP düzeyleri yüksek saptandı. Bu da hsCRP'nin daha yüksek saptandığı morbid obezitenin kardiyovasküler hastalık riskinin artışında önemli bir antite olduğunu göstermektedir.

Comparison of obese patients with and without metabolic syndrome in terms of anthropometric measurements, high sensitive CRP and uric acid levels

Morbidity and mortality increasing effect of obesity is known. In epidemiological investigations a close relation between the increment of patient with metabolic syndrome (MS) and obesity epidemic has been detected. The aim of this study is to evaluate the relationship between anthropometric measurements, high sensitive CRP (hsCRP) and uric acid levels of obese patients with and without MS, which are important at cardiovascular disease risk. Material-Methods: Ninety-six obese patients who applied to policlinic have been evaluated cross-sectionally. Physical examination, anthropometric measurements, liver and renal function tests, lipid parameters, uric acid and hsCRP levels of patients were evaluated. Fifty-eight of 96 obese patients fullfilled the criteria for MS while 38 did not. Results: Seventy-seven of 96 patients (%80) were obese [Body Mass Index (BMI)≥30 kg/m²] and 19 (%20) were morbid obese (BMI≥40 kg/m²). Uric acid levels in men (p=0.00) and hsCRP levels in women (p=0.008) were found higher. When the obese and morbid obese patients with MS were compared; hsCRP levels were statistically higher in the morbid obese group (p=0,036). High sensitive CRP levels were also higher in morbid obese group when the obese and morbid obese patients without MS were matched (p=0.03). Conclusion: In this study hsCRP levels were detected high at morbid obese patients independent from the presence of MS. This shows that morbid obesity where hsCRP is determined higher is an important entity for cardiovascular disease risk increment.

PDF

___

1. Codario R.A. Type 2 Diabetes, Pre-Diabetes and the Metabolic Syndrome: The Primary Guide to Diagnosis and Management. Humana Pres Inc. Totowa, NJ 2005;5: 57-74.
2. Fröhlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, et al. Association between C-reactive protein and features of the metabolic syndrome. Diabetes Care 2000;23(12):1835-9.
3. Fulop T, Tessier D, Carpentier A. The Metabolic Syndrome. Pathol Biol 2006;54(7):375-86.
4. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
5. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-545.
6. Gagliardi ACM, Miname MH, Santos RD. Uric acid: A marker of increased cardiovascular risk. Atherosclerosis 2009;202:11-7.
7. Tamba S, Nishizawa H, Funahashi T, Okauchi Y, Ogawa T, Noguchi M, et al. Relationship between the serum uric acid level, visceral fat accumulation and serum adiponectin concentration in Japanese men. Inter Med 2008;47:1175-80.
8. Garcia-Lorda P, Bullo M, Balanza R, Salas-Salvado J. C-reactive protein, adiposity and cardiovascular risk factors in a Mediterranean population. Int J Obes 2006;30:468-74.
9. Meisinger C, Koenig W, Baumert J, Döring A. Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from general population. The MONICA/ KORA Cohort Study. Arterioscler Thromb Vasc Biol 2008;28:1186-92.
10. Liou TL, Lin MW, Hsiao LC, Tsai TT, Chan WL, Ho LT, et al. Is hyperuricemia another facet of the metabolic syndrome?. J Chin Med Assoc 2006;69:104-9.
11. Strazzullo P, Puig JG. Uric acid and oxidative stress: Relative impact on cardiovascular risk. Nutr Metab Cardiovasc Dis 2007;17(6):409- 14.
12. Özbey N, Molvalılar S, Sencer E, Orhan Y. Şişman kadınlarda metabolik risk göstergesi olarak boy uzunluğunun değeri. Ist Tıp Fak Mecmuası 2001;64:69-73.
13. Pearson TA, Mensah GA, Alexander RW. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107(3):499-511.
14. Eckel RH, Grundy SM, Zimmet ZP. The Metabolic Syndrome. Lancet 2005;365: 1415-28.
15. Chen L, Zhu W, Chen ZW, Di HL, Ren JJ. Relationship between hyperuricemia and metabolic syndrome. J Zhejiang Univ Sci B 2007;8(8): 593-8.
16. Numata T, Miyatake N, Wada J, Makino H. Comparison of serum uric acid levels between Japanese with and without metabolic syndrome. Diabetes Res and Clin Pract 2008;80:e1-5.
17. Sari I, Akar S, Pakoz B, Şişman AR, Gürler O, Birlik M, et al. Hyperuricemia and its related factors in an urban population, Izmir, Turkey. Rheumatol Int 2009;29(8):869–74.
18. Kawada T, Otsuka T, Katsumata M, Suzuki H. Serum uric acid is significantly related to the components of the metabolic syndrome in Japaese workingmen. J Cardiometab Syndr 2007;2(3):158-62.
19. Kawamoto R, Tomita H, Oka Y, Ohtsuka N. Relationship between serum uric acid concentration, metabolic syndrome and carotid atherosclerosis. Intern Med 2006;45:605-14.
20. Hao Z, Konta T, Takasaki S, Abiko H, Ishikawa M, Takahashi T, et al. The association between microalbuminuria and metabolic syndrome in the general population in Japan: the Takahata study. Intern Med 2007;46(7):341-6.
21. Tamakoshi K, Yatsuya H, Kondo T, Hori Y, Ishikawa M, Zhang H, et al. The metabolic syndrome is associated with elevated circulating Creactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord 2003;27(4):443-9.